Cholecystokinin antagonism by anthramycin, a benzodiazepine antibiotic, in the central nervous system in mice

Kubota, Keiichi; Sugaya, Kimio; Koizumi, Yoriko; Toda, Masako

doi:10.1016/0006-8993(89)90666-5

Cited by 7 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, benzodiazepines were very weak in displacing CCK in mouse brain (IC50 = 10 M) [46]. In a study from Japan anthramycin [47], a benzodiazepine derivative, was reported to be a potent antagonists of CCK in mice. Anthramycin reversed CCK-8 induced satiety and was shown to displace [125I] CCK-8 binding in different brain regions, especially in the cortex.…”

Section: Benzodiazepine Derivativesmentioning

confidence: 99%

Breaking into Merck's CCK Patents: the Starting Point of PNB Vesper Life Science to Design and Develop Cholecystokinin(CCK)-Antagonists as Targeted Chemotherapeutics

Lattmann¹

2018

DDIPIJ

View full text Add to dashboard Cite

Early anti-cancer research was dominated by the development of alkylating agents, followed by the discovery of a variety of anti-metabolites, which were useful anti-viral agents at the same time. Current anti-cancer drugs are designed towards molecular targets in order to reduce their toxicity and to enhance the selectivity on the cancer cells. Within an increasingly growing number of molecular targets, the cholecystokinin, as a neuro modulator, became an important anti-cancer target, especially when it was shown that cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via the protein kinase C pathway. The low potency and the lack of subtype receptor selectivity of those early non-peptide CCK-antagonists, was improved in the following generations of CCK antagonists. These potent and selective antagonists have shown disappointing results in clinical trials due to a poor bioavailability. Initially cholecystokinin was discussed as growth factor, not only in pancreatic cancer, but also for lung, breast, colon and brain cancer, followed by a detailed discussion of over 20 different chemical classes having been developed to date, mainly for the area of neuroscience. Loxiglumide, CI-988, Devazepide, L-365,260 and YM022 are highlighted including in vivo studies and clinical trials. Moreover, CCK antagonists were found useful in the enhancement of the analgesic effects of morphine and the anti-neo plastic effect of cis-platinium. Clinical trials are ongoing. It is concluded that non peptidal cholecystokinin receptor antagonists are modern, non-toxic anti-cancer agents.

show abstract

Section: Benzodiazepine Derivativesmentioning

confidence: 99%